Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345332 | 1.00 | KDM4E (0.34) | KDM4EMEN1ALDH1A1POLBMAPT | |
| SCHEMBL4190413 | 0.81 | CCR1 (0.42) | MAPT | |
| SCHEMBL4190419 | 0.81 | CCR1 (0.42) | MAPT | |
| SCHEMBL4343117 | 0.81 | CCR1 (0.42) | MAPT | |
| SCHEMBL4348419 | 0.80 | GAA (0.30) | — | |
| SCHEMBL4189589 | 0.80 | MAPT (0.37) | KDM4EMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL4335626 | 0.80 | MAPT (0.37) | KDM4EMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL5117607 | 0.80 | MAPT (0.37) | KDM4EMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL27767817 | 0.75 | KDM4E (0.30) | KDM4EMEN1ALDH1A1POLBMAPT | |
| SCHEMBL4399411 | 0.70 | ALDH1A1 (0.66) | KDM4EMEN1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | claimed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| EP-2027105-A2 | NOVEL PROCESS FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064884-A1 | Novel Process 1 | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129960-A2 | NOVEL PROCESSES FOR PREPARING INTERMEDIATES OF CCR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064884-A1 | Novel Process 1 | TPX2, UGT1A1, BRIX1 | KDM4E 2494/4885MEN1 726/4885ALDH1A1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.